You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

HYDROXOCOBALAMIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Hydroxocobalamin, and when can generic versions of Hydroxocobalamin launch?

Hydroxocobalamin is a drug marketed by Abraxis Pharm, Actavis, and Watson Labs. and is included in three NDAs.

The generic ingredient in HYDROXOCOBALAMIN is hydroxocobalamin. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxocobalamin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Hydroxocobalamin

A generic version of HYDROXOCOBALAMIN was approved as hydroxocobalamin by ACTAVIS on December 31st, 1969.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for HYDROXOCOBALAMIN?
  • What are the global sales for HYDROXOCOBALAMIN?
  • What is Average Wholesale Price for HYDROXOCOBALAMIN?
Drug patent expirations by year for HYDROXOCOBALAMIN
Drug Prices for HYDROXOCOBALAMIN

See drug prices for HYDROXOCOBALAMIN

Recent Clinical Trials for HYDROXOCOBALAMIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 4
General Oncology, Inc.Phase 1
Joshua KorzenikPhase 2

See all HYDROXOCOBALAMIN clinical trials

Pharmacology for HYDROXOCOBALAMIN
Drug ClassAntidote
Medical Subject Heading (MeSH) Categories for HYDROXOCOBALAMIN

US Patents and Regulatory Information for HYDROXOCOBALAMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm HYDROXOCOBALAMIN hydroxocobalamin INJECTABLE;INJECTION 084921-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Actavis HYDROXOCOBALAMIN hydroxocobalamin INJECTABLE;INJECTION 085998-001 Approved Prior to Jan 1, 1982 RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Watson Labs HYDROXOCOBALAMIN hydroxocobalamin INJECTABLE;INJECTION 085528-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for HYDROXOCOBALAMIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
SERB SA Cyanokit hydroxocobalamin EMEA/H/C/000806
Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures.
Authorised no no no 2007-11-23
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

HYDROXOCOBALAMIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Hydroxocobalamin

Introduction

Hydroxocobalamin, a form of vitamin B12, is a crucial medication used in the management and treatment of vitamin B12 deficiency and acute cyanide toxicity. Here, we delve into the market dynamics and financial trajectory of hydroxocobalamin, highlighting key factors driving its growth and challenges it faces.

Global Vitamin B12 Market Overview

The global vitamin B12 market, which includes hydroxocobalamin, is projected to experience significant growth. The market size is expected to increase from $205.0 million in 2024 to $346.6 million by 2032, at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period[1].

Market Segmentation

The vitamin B12 market is segmented by type, application, and geography.

By Type

  • Hydroxocobalamin: While cyanocobalamin holds the majority share due to its stability and cost-effectiveness, hydroxocobalamin is gaining traction for its specific medical applications. It is particularly useful in treating vitamin B12 deficiency secondary to conditions that impair GI tract absorption, such as malabsorption and pernicious anemia[2].

By Application

  • Pharmaceutical Industry: Hydroxocobalamin is widely used in the pharmaceutical industry for treating macrocytic anemia, Leber optic atrophy, and as an antidote for cyanide poisoning. The growing demand for these treatments is a key driver for the segment[2].
  • Food & Nutraceuticals Industry: Although hydroxocobalamin is not as commonly used in food fortification as other forms of vitamin B12, the overall growth in the food & nutraceuticals industry contributes to the broader market dynamics[1].

Key Drivers of Growth

Several factors are driving the growth of the hydroxocobalamin market:

Increasing Prevalence of Vitamin B12 Deficiency

The rising prevalence of chronic diseases, pernicious anemia, and vitamin B12 deficiency are significant drivers. As the global population ages and the incidence of these conditions increases, the demand for hydroxocobalamin is expected to rise[1].

Growing Health Awareness

Increased health awareness among consumers is leading to a higher demand for vitamin B12 supplements, including hydroxocobalamin. This trend is particularly pronounced in regions with advanced healthcare sectors focusing on preventative care[1].

Medical Applications

Hydroxocobalamin's unique medical applications, such as treating cyanide poisoning and neurological conditions, make it an essential product in the pharmaceutical industry. The FDA-approved form of intravenous hydroxocobalamin for cyanide poisoning further solidifies its market position[2].

Regional Market Dynamics

The market for hydroxocobalamin varies significantly across different regions:

Europe

Europe is anticipated to grow rapidly due to advancements in research and innovation in the healthcare and nutrition industries. The high prevalence of pernicious anemia in this region also contributes to the demand for hydroxocobalamin[1].

North America

North America holds a considerable share in the market, driven by the advanced healthcare sector, the availability of a wide range of products, and the growing prevalence of neural conditions and gastrointestinal issues[1].

Asia Pacific

The Asia Pacific region, particularly China, plays a crucial role in the production of vitamin B12, including hydroxocobalamin. However, the market growth in this region is also influenced by the increasing awareness and rising prevalence of Neglected Tropical Diseases (NTDs) and micronutrient malnourishment[1].

Challenges

Despite the growth potential, the hydroxocobalamin market faces several challenges:

High Production Costs

The commercial production of cobalamin, including hydroxocobalamin, is primarily through fermentation, which increases production costs. The dominance of a few key manufacturers and the large dependence on China for supply further exacerbate these costs[1].

Market Concentration

The market is dominated by a few key players such as EUROAPI, CSPC Pharmaceutical Group Co., Ltd., and Ningxia Kingvit Pharmaceutical. This concentration can lead to higher prices and reduced competition[1].

Financial Trajectory

The financial trajectory of the hydroxocobalamin market is closely tied to the overall vitamin B12 market:

Market Size and Growth

The global vitamin B12 market, including hydroxocobalamin, is valued at around $288 million in 2024 and is projected to register a CAGR of around 9.19% during the forecast period of 2024-2030[4].

Revenue Segments

The revenue from hydroxocobalamin is expected to grow significantly due to its increasing use in pharmaceutical applications. The segment's growth is driven by the demand for treatments of vitamin B12 deficiency and cyanide poisoning[2].

Key Players

Major players in the vitamin B12 market, including hydroxocobalamin, are:

  • EUROAPI
  • CSPC Pharmaceutical Group Co., Ltd.
  • Ningxia Kingvit Pharmaceutical
  • Hebei Yuxing

These companies are investing in research and development to enhance production technologies and expand their product portfolios[1].

Conclusion

The market for hydroxocobalamin is poised for significant growth driven by increasing health awareness, rising prevalence of vitamin B12 deficiency, and its unique medical applications. However, the market faces challenges such as high production costs and market concentration. As the global demand for vitamin B12 supplements continues to rise, hydroxocobalamin is expected to play a crucial role in the pharmaceutical and healthcare sectors.

Key Takeaways

  • The global vitamin B12 market, including hydroxocobalamin, is projected to grow at a CAGR of 6.8% from 2024 to 2032.
  • Hydroxocobalamin is used in treating vitamin B12 deficiency and cyanide poisoning.
  • The market is driven by growing health awareness and the increasing prevalence of chronic diseases.
  • Europe and North America are significant regions for the market due to advanced healthcare sectors and high prevalence of pernicious anemia.
  • High production costs and market concentration are key challenges.

FAQs

Q: What are the primary medical applications of hydroxocobalamin? A: Hydroxocobalamin is used in the prevention and treatment of macrocytic anemia associated with vitamin B12 deficiency, Leber optic atrophy, and as an antidote for cyanide poisoning[2].

Q: Which regions are expected to drive the growth of the hydroxocobalamin market? A: Europe and North America are anticipated to drive the growth due to advancements in healthcare and the high prevalence of pernicious anemia[1].

Q: What are the challenges facing the hydroxocobalamin market? A: High production costs due to fermentation and market concentration among a few key manufacturers are significant challenges[1].

Q: Who are the major players in the vitamin B12 market, including hydroxocobalamin? A: Major players include EUROAPI, CSPC Pharmaceutical Group Co., Ltd., and Ningxia Kingvit Pharmaceutical[1].

Q: What is the projected CAGR for the global vitamin B12 market from 2024 to 2032? A: The global vitamin B12 market is projected to grow at a CAGR of 6.8% from 2024 to 2032[1].

Sources

  1. Fortune Business Insights - Vitamin B12 Market Size, Share, Growth | Industry Report [2032][1]
  2. NCBI Bookshelf - Hydroxocobalamin - StatPearls[2]
  3. Market Research Intellect - Global vitamin b12 cyanocobalamin market size forecast[3]
  4. MarkNtel Advisors - Vitamin B12 Market Share, Industry Size, Forecast 2030[4]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.